SEC Form 4
------------

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person <sup>*</sup>	2. Issuer Name and Ticker or Trading Symbol KEMPHARM, INC [KMPH]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
Pascoe Richard W		X Director 10% Owner									
	-	X Officer (give title Other (specify									
(Last) (First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)	below) below)									
C/O KEMPHARM, INC.	01/13/2023	Chief Executive Officer									
1180 CELEBRATION BOULEVARD, SUITE 10	3										
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable									
(Street)		Line)									
CELEBRATION FL 34747		X Form filed by One Reporting Person									
		Form filed by More than One Reporting									
P	=	Person									
(City) (State) (Zip)											

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	(D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	01/13/2023		Р		9,500	Α	\$5.4399	19,973	D	

#### 2. Conversion or Exercise Price of Price of Price of Date 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Date 5. Number Transaction Date 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities 8. Price of Derivative Securities 9. Number of derivative Securities 10. Ownership Securities 11. Nature of Indirect Beneficial Ownership Ownership

Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code (Instr. 8)		Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		(Month/Day/Year)		Securities Underlying Derivative Security (Instr. 3 and 4)		Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					

Explanation of Responses:

1. Title of Derivative

#### /s/ Timothy J. Sangiovanni,

Attorney-in-Fact for Richard 01/13/2023 W. Pascoe

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{*}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.